XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.
R
R

Regeneron


뉴스

U.S. BioNTech, Honeywell International, Klaviyo

U.S. RESEARCH ROUNDUP-BioNTech, Honeywell International, Klaviyo June 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Biontech, Honeywell International and Klaviyo, on Wednesday. HIGHLIGHTS * BioNTech SE BNTX.O : JP Morgan raises target price to $94 from $90 * Honeywell International Inc HON.O : HSBC raises target price to $235 from $200 * Klaviyo Inc KVYO.N : Barclays raises to overweight from equal weight * NetA
A
F
G
N
R
G
D
M

New Pharma will crowd out Big Pharma

BREAKINGVIEWS-New Pharma will crowd out Big Pharma The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, June 11 (Reuters Breakingviews) - Big Pharma is under threat from tech-driven upstart rivals. The values of large, established players like $159 billion Pfizer PFE.N , $230 billion Novartis NOVN.S and $216 billion Roche ROG.S are converging with newer players like $121 billion Vertex Pharmaceuticals VRTX.O .
A
G
N
P
R
R
S
V

U.S. Honeywell International, Stericycle, Target Corp

CORRECTED-U.S. RESEARCH ROUNDUP-Honeywell International, Stericycle, Target Corp Corrects Elf Beauty entry to say TD Cowen raises, not cuts, target price to $235 from $190 June 4 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.listed companies, including Honeywell International, Stericycle and Target Corp on Tuesday.
A
B
M
N
Q
R
S
S
T
I
S

EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review

UPDATE 1-EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review Adds details from EMA disclosure and background throughout May 31 (Reuters) - Sanofi SASY.PA and partner Regeneron Pharmaceuticals REGN.O have secured the European regulator's backing for use of Dupixent in patients with a chronic lung disease even as the U.S. Food and Drug Administration (FDA) extended its review.
R
S

FDA extends deadline, requests more data on Sanofi's Dupixent for treating 'smoker's lung'

FDA extends deadline, requests more data on Sanofi's Dupixent for treating 'smoker's lung' May 31 (Reuters) - French drugmaker Sanofi SASY.PA and its partner Regeneron REGN.O said on Friday the U.S. Food and Drug Administration (FDA) requested additional analyses on the efficacy of Dupixent as an add-on treatment in certain patients 'smoker's lung', or COPD.
R
S

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch May 31 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. RENAULT RENA.PA The French automaker and Chinese peer Geely on Friday announced the creation of a 50-50 joint venture for hybrid and combustion powertrain components and systems.
R
R
S
T
V
F
N
U

Regeneron Pharmaceuticals Says European Commission Is Expected To Announce Final Decision On Dupixent Application In Coming Months.

BRIEF-Regeneron Pharmaceuticals Says European Commission Is Expected To Announce Final Decision On Dupixent Application In Coming Months. May 31 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : DUPIXENT® (DUPILUMAB) RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT PATIENTS WITH COPD EUROPEAN COMMISSION IS EXPECTED TO ANNOUNCE A FINAL DECISION ON DUPIXENT APPLICATION IN COMING MONTHS.
R
S

Sanofi: FDA Extends Review Of Dupixent For Treatment Of COPD Patients

BRIEF-Sanofi: FDA Extends Review Of Dupixent For Treatment Of COPD Patients May 31 (Reuters) - Sanofi SA SASY.PA : UPDATE ON FDA PRIORITY REVIEW OF DUPIXENT FOR TREATMENT OF COPD PATIENTS WITH TYPE 2 INFLAMMATION US FOOD AND DRUG ADMINISTRATION (FDA) HAS EXTENDED BY THREE MONTHS TARGET ACTION DATE OF ITS PRIORITY REVIEW OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR DUPIXENT (DUPILUMAB) REVISED TARGET ACTION DATE IS SEPTEMBER 27, 2024 FDA DID NOT RAISE ANY CONCERNS REGARDING APPROVABIL
R
S

Regeneron Issues Update On FDA Priority Review Of Dupixent

BRIEF-Regeneron Issues Update On FDA Priority Review Of Dupixent May 31 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : UPDATE ON FDA PRIORITY REVIEW OF DUPIXENT® (DUPILUMAB) FOR THE TREATMENT OF COPD PATIENTS WITH TYPE 2 INFLAMMATION FDA DID NOT RAISE ANY CONCERNS REGARDING APPROVABILITY OF DUPIXENT FOR THIS INDICATION. REVISED TARGET ACTION D
R
S

Biohaven Doses First Patient With Novel Trop-2 Directed Antibody Drug Conjugate (Adc) Bhv-1510 In Advanced Or Metastatic Epithelial Tumors

BRIEF-Biohaven Doses First Patient With Novel Trop-2 Directed Antibody Drug Conjugate (Adc) Bhv-1510 In Advanced Or Metastatic Epithelial Tumors May 29 (Reuters) - Biohaven Ltd BHVN.N : BIOHAVEN LTD: DOSES FIRST PATIENT WITH NOVEL TROP-2 DIRECTED ANTIBODY DRUG CONJUGATE (ADC) BHV-1510 IN ADVANCED OR METASTATIC EPITHELIAL TUMORS BIOHAVEN: GOT INTO C
R

Regeneron Says Promising Anti-Tumor Activity Of Novel Costimulatory Bispecific Antibody To Be Reported At Asco

BRIEF-Regeneron Says Promising Anti-Tumor Activity Of Novel Costimulatory Bispecific Antibody To Be Reported At Asco May 23 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : PROMISING ANTI-TUMOR ACTIVITY OF NOVEL COSTIMULATORY BISPECIFIC ANTIBODY REGN7075 (EGFRXCD28) IN COMBINATION WITH LIBTAYO® (CEMIPLIMAB) TO BE REPORTED AT ASCO REGENERON PHARM
R

U.S. Chemed, PTC Therapeutics, Regeneron Pharmaceuticals

U.S. RESEARCH ROUNDUP- Chemed, PTC Therapeutics, Regeneron Pharmaceuticals May 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Chemed, PTC Therapeutics and Regeneron Pharmaceuticals, on Tuesday. HIGHLIGHTS * Chemed Corp CHE.N : RBC cuts target price to $697 from $712 * Deckers Brands DECK.N : Barclays cuts target price to $1,026 from $1,110 * PTC Therapeutics Inc PTCT.O : Raymond James raises to market perform fro
E
I
J
N
R
D
E
A
K

US FDA approves two biosimilars for blockbuster eye drug Eylea

UPDATE 2-US FDA approves two biosimilars for blockbuster eye drug Eylea Adds background in paragraphs 2-4 May 20 (Reuters) - The U.S. Food and Drug Administration ( FDA) on Monday approved two close copies of Regeneron Pharmaceuticals' REGN.O Eylea, its first-ever clearance to biosimilar versions of the blockbuster eye treatment. The agency approved Biocon Biologics' Yesafili as well as Samsung Bioepis and Biogen's BIIB.O Opuviz, while also allowing interchangeability, or the drug's substitution
A
B
R

US FDA approves Biocon unit's biosimilar to blockbuster eye drug Eylea

US FDA approves Biocon unit's biosimilar to blockbuster eye drug Eylea May 20 (Reuters) - The U.S. Food and Drug Administration on Monday approved Biocon BION.NS unit's biosimilar to Regeneron Pharmaceuticals' REGN.O blockbuster eye drug Eylea, according to information on the agency's website. Reporting by Leroy Leo in Bengaluru; Editing by Shilpi
R

U.S. Arista Networks, Crescent Energy, Dell Technologies

U.S. RESEARCH ROUNDUP-Arista Networks, Crescent Energy, Dell Technologies May 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Arista Networks, Crescent Energy and Dell Technologies, on Monday. HIGHLIGHTS * Arista Networks Inc ANET.N : Evercore ISI raises target price to $340 from $320 * Crescent Energy Co CRGY.N : Gerdes Energy Research raises to buy from neutral * Dell Technologies Inc DELL.N : JP Morgan raises t
N
R
A
K
T
D
H
A
A
H

U.S. STOCKS Cracker Barrel, Robinhood Markets, DuPont

BUZZ-U.S. STOCKS ON THE MOVE-Cracker Barrel, Robinhood Markets, DuPont Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were little changed on Friday as investors took a breather from the week's rally driven by growing expectations of U.S.
A
C
C
G
R
S
A
L
T
U
U
U
A
D
L

U.S. STOCKS Tilray Brands, Arbutus Biopharma, Coinbase

BUZZ-U.S. STOCKS ON THE MOVE-Tilray Brands, Arbutus Biopharma, Coinbase Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were little changed on Friday as investors took a breather from the week's rally driven by growing expectations of U.S.
A
C
C
E
G
M
N
R
S
A
T
U
U
U
A
D
L

U.S. STOCKS Advanced Micro Devices, United Airlines, GameStop

BUZZ-U.S. STOCKS ON THE MOVE-Advanced Micro Devices, United Airlines, GameStop Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were set to open marginally higher on Friday, looking to extend this week's rally on growing expectations of U.S.
A
G
M
N
R
A
T
U
U
A
D
L

U.S. STOCKS DXC Technology, Darden Restaurants, Doximity

BUZZ-U.S. STOCKS ON THE MOVE-DXC Technology, Darden Restaurants, Doximity Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures were treading water on Friday, signaling a pause on Wall Street after a rally driven by expectations of interest-rate cuts this year.
A
C
G
R
T
U
D
L

Brokerages await lung disease drug data from Amgen

BUZZ-Brokerages await lung disease drug data from Amgen ** Brokerages await trial data presentations from Amgen AMGN.O and Regeneron REGN.O on Sunday as both companies vie for market share with their experimental treatments for chronic obstructive pulmonary disease (COPD) ** BMO Capital Markets believes investors will focus on how AMGN's drug Tezspire compares to REGN's Dupixent in COPD patients with high count of a type of white blood cell called eosinophil ** J.P.Morgan says Tezspire's mid-sta
A
J
R



조건

인기 자산

면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.

온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.

이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.

리스크 경고: 고객님의 자본이 위험에 노출 될 수 있습니다. 레버리지 상품은 모든 분들에게 적합하지 않을수 있습니다. 당사의 리스크 공시를 참고하시기 바랍니다.